股票 › EW
爱德华生命科学 EW
美股市值排名 #376
$102.14 +$1.32 (+1.31%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $102.14 0.00%
开盘$99.00
昨收$100.82
当日区间$98.50 – $102.19
成交量5.11M
市值$58.73B
市盈率（TTM）57.7
股息率–
基本面
最新报告季度：Q2, ended Jun 2026
营收$1.74B+13.6% YoY
营业利润$519.50M+20.6% YoY
净利润$241.40M-27.2% YoY
摊薄每股收益$0.42-25.0% YoY
自由现金流$585.00M+142.8% YoY
经营现金流$651.90M
营收，近8个季度
净利润，近8个季度
各季度摊薄每股收益
各季度自由现金流
年度营收
盈利能力与资产负债表
毛利率77.8%
营业利润率28.1%
净利率15.4%
净资产收益率9.5%
资产收益率7.3%
投入资本回报率7.9%
流动比率4.52
负债/资产比率22.7%
现金及投资$4.25B
总负债$680.30M
净现金（净负债）$3.57B
自由现金流/营收22.0%
营收构成
2026/Q2 季度
按业务线
利润表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 报告营业总收入 | $1.74B | $1.65B | $6.07B | $1.57B | $1.55B |
| 营业总收入 | $1.74B | $1.65B | $6.07B | $1.57B | $1.55B |
| 营业成本 | $392.40M | $362.60M | $1.33B | $343.00M | $345.20M |
| 毛利润 | $1.35B | $1.29B | $4.73B | $1.23B | $1.21B |
| 营业费用 | $829.10M | $771.30M | $3.10B | $856.30M | $782.80M |
| 销售及管理费用 | $561.20M | $522.20M | $2.09B | $602.90M | $514.60M |
| 研发费用 | $278.90M | $263.30M | $1.08B | $267.70M | $280.70M |
| 其他营业费用 | -$11.00M | -$14.20M | -$67.20M | -$14.30M | -$12.50M |
| 营业利润 | $519.50M | $514.70M | $1.64B | $370.30M | $425.10M |
| 非经营性利息净收入（支出） | $30.00M | $33.50M | $148.40M | $35.90M | $38.60M |
| 非经营性利息收入 | $30.00M | – | $168.80M | $56.30M | $38.60M |
| 其他收入（支出） | -$29.70M | -$89.20M | -$511.70M | -$315.80M | -$115.30M |
| 特殊收益（费用） | -$46.30M | -$160.70M | -$518.90M | -$319.00M | -$118.00M |
| -减：重组及并购费用 | $0.00 | $0.00 | $6.60M | $10.60M | -$12.40M |
| -减：其他特殊支出 | $6.30M | $37.10M | $325.40M | $208.60M | $90.40M |
| -减：核销 | $40.00M | $123.60M | $146.90M | $99.80M | $0.00 |
| 其他非经营性收入（支出） | $16.60M | $71.50M | $3.20M | -$800,000.00 | $2.70M |
| 税前利润 | $519.80M | $459.00M | $1.27B | $90.40M | $348.40M |
| 税费 | $278.40M | $78.30M | $216.90M | $26.20M | $56.10M |
| 净利润 | $241.40M | $380.70M | $1.07B | $91.20M | $290.30M |
| 持续经营利润 | $241.40M | $380.70M | $1.06B | $64.20M | $292.30M |
| 终止经营净利润 | $0.00 | $0.00 | $13.40M | $27.00M | -$2.00M |
| 少数股东权益 | -$500,000.00 | $0.00 | -$4.10M | $0.00 | -$800,000.00 |
| 归属母公司净利润 | $241.90M | $380.70M | $1.07B | $91.20M | $291.10M |
| 归属普通股股东净利润 | $241.90M | $380.70M | $1.07B | $91.20M | $291.10M |
| 基本每股收益 | $0.42 | $0.66 | $1.84 | $0.16 | $0.50 |
| 摊薄每股收益 | $0.42 | $0.66 | $1.83 | $0.16 | $0.50 |
| 其他财务成本合计 | – | -$33.50M | – | – | – |
| 非经营性利息支出 | – | – | $20.40M | – | – |
| 证券出售收益 | – | – | $4.00M | – | – |
| -减：资本性资产减值 | – | – | $40.00M | $0.00 | $40.00M |
资产负债表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 总资产 | $13.87B | $13.32B | $13.70B | $13.70B | $13.27B |
| 流动资产合计 | $6.82B | $6.23B | $6.74B | $6.74B | $6.36B |
| 现金及现金等价物与短期投资 | $4.25B | $3.67B | $4.23B | $4.23B | $3.84B |
| -现金及现金等价物 | $2.91B | $2.45B | $2.94B | $2.94B | $2.69B |
| -短期投资 | $1.35B | $1.23B | $1.29B | $1.29B | $1.16B |
| 应收款 | $955.70M | $973.00M | $912.10M | $912.10M | $892.80M |
| -应收账款 | $770.40M | $775.70M | $659.60M | $659.60M | $693.30M |
| -其他应收款 | $185.30M | $197.30M | $252.50M | $252.50M | $199.50M |
| 预付资产 | $119.00M | $135.70M | $135.00M | $135.00M | $125.20M |
| 存货 | $1.13B | $1.12B | $1.13B | $1.13B | $1.14B |
| 其他流动资产 | $360.30M | $329.50M | $339.30M | $339.30M | $323.40M |
| 非流动资产合计 | $7.05B | $7.09B | $6.96B | $6.96B | $6.91B |
| 固定资产净值 | $1.94B | $1.92B | $1.91B | $1.91B | $1.84B |
| -固定资产原值 | $1.94B | $1.92B | $2.76B | $2.76B | $1.84B |
| 投资及预付款 | $244.10M | $285.60M | $278.60M | $278.60M | $274.70M |
| 金融资产 | $14.60M | $14.20M | $5.80M | $5.80M | $5.10M |
| 一年以上应收账款 | $412.10M | $400.10M | $314.80M | $314.80M | $303.90M |
| 一年以上应收票据 | $68.80M | $137.20M | $173.70M | $173.70M | $227.30M |
| 一年以上预付资产 | $89.20M | $91.30M | $93.30M | $93.30M | $95.70M |
| 商誉及其他无形资产 | $3.33B | $3.05B | $2.90B | $2.90B | $2.90B |
| -商誉 | $1.95B | $1.82B | $1.77B | $1.77B | $1.77B |
| -其他无形资产 | $1.38B | $1.23B | $1.13B | $1.13B | $1.13B |
| 一年以上递延资产 | $911.80M | $1.10B | $1.14B | $1.14B | $1.10B |
| 其他非流动资产 | $31.70M | $96.10M | $142.60M | $142.60M | $167.60M |
| 负债合计 | $3.14B | $2.99B | $3.36B | $3.36B | $3.07B |
| 流动负债合计 | $1.51B | $1.41B | $1.81B | $1.81B | $1.59B |
| 应付款 | $481.00M | $475.40M | $504.90M | $504.90M | $388.00M |
| -应付账款 | $210.50M | $181.10M | $227.50M | $227.50M | $165.00M |
| -应付税款合计 | $270.50M | $294.30M | $277.40M | $277.40M | $223.00M |
| 一年内应计费用 | $595.80M | $606.00M | $714.30M | $714.30M | $601.00M |
| 短期债务及融资租赁负债 | $24.10M | $24.30M | $24.50M | $24.50M | $26.80M |
| -一年内到期融资租赁负债 | $24.10M | $24.30M | $24.50M | $24.50M | $26.80M |
| 一年内预提费用 | $7.50M | $7.50M | $50.00M | $50.00M | $64.80M |
| 一年内递延负债 | $20.30M | $22.80M | $27.20M | $27.20M | $33.20M |
| 其他流动负债 | $6.30M | $7.60M | $25.30M | $25.30M | $36.80M |
| 非流动负债合计 | $1.63B | $1.58B | $1.55B | $1.55B | $1.48B |
| 长期债务及融资租赁负债 | $680.30M | $678.60M | $680.90M | $680.90M | $673.50M |
| -长期债务 | $598.70M | $598.50M | $598.30M | $598.30M | $598.20M |
| -长期融资租赁负债 | $81.60M | $80.10M | $82.60M | $82.60M | $75.30M |
| 其他非流动负债 | $954.00M | $906.10M | $865.00M | $865.00M | $805.50M |
| 股东权益合计 | $10.72B | $10.33B | $10.34B | $10.34B | $10.21B |
| 股东权益 | $10.62B | $10.33B | $10.34B | $10.34B | $10.21B |
| 股本 | $661.70M | $660.00M | $658.70M | $658.70M | $658.20M |
| -普通股 | $661.70M | $660.00M | $658.70M | $658.70M | $658.20M |
| -优先股 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 资本公积 | $2.98B | $2.78B | $2.77B | $2.77B | $2.70B |
| 留存收益 | $14.86B | $14.62B | $14.24B | $14.24B | $14.15B |
| 减：库存股 | $7.67B | $7.51B | $7.09B | $7.09B | $7.05B |
| 不影响留存收益的损益 | -$214.60M | -$221.30M | -$238.30M | -$238.30M | -$250.40M |
| 少数股东权益 | $106.90M | – | $0.00 | $0.00 | $0.00 |
| -累计折旧 | – | – | -$849.80M | -$849.80M | – |
| -可供出售证券 | – | – | $243.90M | $243.90M | $240.70M |
| -长期股权投资 | – | – | $34.70M | $34.70M | $34.00M |
| 一年以上应计费用 | – | – | $0.00 | $0.00 | – |
| -持有至到期证券 | – | – | – | – | $0.00 |
现金流量表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 经营活动现金流 | $651.90M | $43.80M | $1.60B | $450.90M | $573.70M |
| 持续经营经营活动现金流净额 | $651.90M | $43.80M | $1.60B | $450.90M | $573.70M |
| 持续经营净利润 | $241.40M | $380.70M | $1.07B | $91.20M | $290.30M |
| 折旧、折耗与摊销 | $42.70M | $40.90M | $156.60M | $42.70M | $39.20M |
| 递延税款 | $181.30M | $9.40M | -$117.60M | -$54.40M | -$18.00M |
| 其他非现金项目 | -$24.10M | -$58.20M | -$12.80M | -$21.90M | -$11.70M |
| 营运资金变动 | $131.90M | -$501.50M | $154.60M | $254.30M | $192.70M |
| -应收款变动 | -$10.20M | -$117.90M | -$23.00M | $32.40M | $13.20M |
| -存货变动 | -$23.50M | -$1.60M | $50.70M | $11.00M | -$1.80M |
| -预付资产变动 | $29.50M | -$8.70M | -$15.40M | $2.10M | -$14.20M |
| -应付账款及应计费用变动 | $123.70M | -$397.10M | $318.60M | $153.90M | $213.60M |
| -其他营运资金变动 | $12.40M | $23.80M | -$176.30M | $54.90M | -$18.10M |
| 投资活动现金流净额 | -$193.20M | -$92.80M | -$712.90M | -$198.30M | -$427.80M |
| 持续经营投资活动现金流净额 | -$193.20M | -$92.80M | -$712.90M | -$198.30M | -$427.80M |
| 资本支出 | -$66.90M | -$64.90M | -$260.20M | -$97.40M | -$57.50M |
| 业务购买及出售净额 | -$5.70M | -$41.40M | -$101.10M | -$15.00M | -$37.80M |
| 投资购置及出售净额 | -$115.60M | $69.00M | -$282.10M | -$117.70M | -$341.50M |
| 其他投资变动净额 | -$5.00M | -$55.50M | -$69.50M | $31.80M | $9.00M |
| 筹资活动现金流 | -$300,000.00 | -$451.20M | -$956.80M | -$11.40M | -$740.10M |
| 持续经营筹资活动现金流净额 | -$300,000.00 | -$451.20M | -$956.80M | -$11.40M | -$740.10M |
| 普通股发行净额 | -$153.30M | -$421.80M | -$893.40M | -$40.60M | -$588.70M |
| 股票期权行使所得 | $53.80M | $68.90M | $174.10M | $32.30M | $34.70M |
| 其他筹资费用净额 | $99.20M | -$98.30M | -$237.50M | -$3.10M | -$186.10M |
| 期末现金余额 | $2.91B | $2.45B | $2.94B | $2.94B | $2.69B |
| 现金净变动 | $458.40M | -$500.20M | -$74.50M | $241.20M | -$594.20M |
| 期初现金余额 | $2.45B | $2.94B | $3.06B | $2.69B | $3.29B |
| 汇率变动影响 | $3.80M | $8.20M | -$44.80M | $3.50M | -$1.00M |
| 自由现金流 | $585.00M | -$21.10M | $1.34B | $353.50M | $516.20M |
| 持续经营损益 | – | $3.50M | – | – | – |
| 无形资产购置及出售净额 | – | – | $0.00 | $0.00 | – |
暂无评论——快来第一个聊聊 EW。
登录后参与讨论。